e-learning
resources
Munich 2006
Wednesday 06.09.2006
Airway cell biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease
E. M. Drost, C. A. Poland, K. Donaldson, W. MacNee (Edinburgh, United Kingdom)
Source:
Annual Congress 2006 - Airway cell biology
Session:
Airway cell biology
Session type:
Poster Discussion
Number:
4935
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. M. Drost, C. A. Poland, K. Donaldson, W. MacNee (Edinburgh, United Kingdom). Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease. Eur Respir J 2006; 28: Suppl. 50, 4935
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Peroxisome proliferator-activated receptors: a therapeutic target in COPD?
Source: Eur Respir J 2008; 31: 502-508
Year: 2008
Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD
Source: Eur Respir J 2007; 30: 245-252
Year: 2007
Reduced expression of peroxisome proliferator-activated receptors (PPARs) in skeletal muscle of patients with COPD
Source: Annual Congress 2006 - Respiratory muscles
Year: 2006
The role of peroxisome proliferator-activated receptor γ in pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Peroxisome proliferator-activated receptor-α reduces inflammation and vascular leakage in a murine model of acute lung injury
Source: Eur Respir J 2008; 32: 1344-1353
Year: 2008
Relationship between peroxisome proliferator-activated receptor α and neutrophils in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 452s
Year: 2004
Peroxisome proliferator-activated receptor gamma (PPARγ) protects against pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2007; 30: Suppl. 51, 6s
Year: 2007
Preserved compliance and reduced inflammation after activation of peroxisome proliferator-activated receptor (PPAR)a in a murine model of acute lung injury
Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS)
Year: 2006
Role of exogenous ligands for the peroxisome proliferator-activated receptor-β/δ in the development of bleomycin-induced lung injury
Source: Annual Congress 2010 - Cell biology and immunology of lung disease
Year: 2010
Impacts of peroxisome proliferator-activated receptor gamma activation on cigarette smoke-induced exacerbated response to bacteria
Source: Eur Respir J 2015; 45: 191-200
Year: 2015
The effects of exercise training on peroxisome proliferator-activated receptor (PPAR) expression in skeletal muscle in COPD
Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation
Year: 2009
The effect of peroxisome proliferator-activated receptor-? ligands on in vitro and in vivo models of COPD
Source: Eur Respir J 2014; 43: 409-420
Year: 2013
Peroxisome proliferator-activated receptor γ inhibits acrolein-induced airway mucus hypersecretion in rats
Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD
Year: 2008
PPAR-γ agonists as therapy for diseases involving airway neutrophilia
Source: Eur Respir J 2004; 24: 18-23
Year: 2004
Role of NF-?B and PPAR-? in lung inflammation induced by monocyte-derived microparticles
Source: Eur Respir J 2011; 37: 1494-1502
Year: 2011
Activation of airway epithelial cell inhibited by peroxisome proliferator-activated receptor γ
Source: Eur Respir J 2006; 28: Suppl. 50, 229s
Year: 2006
The interaction of glucocorticoid and peroxisome proliferator-activated receptor γ agonist in asthmatic mice
Source: Eur Respir J 2006; 28: Suppl. 50, 226s
Year: 2006
Transcriptional regulation of the human cystic fibrosis transmembrane conductance regulator gene promoter by peroxisome proliferator-activated receptor γ
Source: Eur Respir J 2007; 30: Suppl. 51, 38s
Year: 2007
Role of peroxisome proliferator activated receptor γ in COPD
Source: Annual Congress 2009 - Airway inflammation and host defence
Year: 2009
Effects of peroxisome proliferators-activated receptor-α, γ agonists on acute lung injury rats induced by lipopolysaccharide
Source: Eur Respir J 2006; 28: Suppl. 50, 397s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept